Twitxy Saved

Devika Das, MD, MSHQS, FASCO

@DevikaDasMD

Division Director of Hematology/Oncology, Associate Director - Clinical Affairs at the cancer institute @ummc_cancer @ummcMedicine
🫁 Oncology, QI/Safety Expert
Madison,MS instagram.com/devikadasmd?ig… Joined October 2017
2.8K Following 5.8K Followers 9.9K Posts

Latest posts 5

Devika Das, MD, MSHQS, FASCO @DevikaDasMD
Great opportunity to be part of a mission driven team. Everyone here is passionate about building a high quality cancer program for Mississippians! Meet the team at #ASTRO26 πŸ‘πŸ‘πŸ‘
UMMC Radiation Oncology Residency Verified account @UMMC_RadOncRes Sep 15
Many places. One team. One Mississippi home. Our UMMC #radonc team has come together from across the U.S. and around the world, bringing different experiences and perspectives to one shared mission: caring for Mississippi. Heading to #ASTRO26? Come meet us at Booth #1559 and learn more about opportunities to build your career, community, and future in Mississippi. Interested in connecting? Scan the QR code and let us know you’re coming.
View quoted post on X
Devika Das, MD, MSHQS, FASCO @DevikaDasMD
Publication alert! 🚨 Grateful to be included in this SEER data base analysis.
🧐 Hypothesis generating observations which could use lead to further study and improvement projects.
πŸ“I suspect a lot of heath and screening behaviors leading to seasonal cancer diagnosis are around health care access challenges including meeting deductibles etc and cancer awareness months and activities do help. Congratulations to the wonderful authors/ my colleagues πŸ‘πŸ‘
@AYasinzaiMD @TGeorgeMD @JAMANetworkOpen
jamanetwork.com/journals/jaman…
Devika Das, MD, MSHQS, FASCO @DevikaDasMD
Rural academic thoracic oncology perspective as I am now parsing through the #WCLC26 data #lcsm
Great year and momentum for #SCLC
πŸ“ Maverick data is phenomenal to spare patients PCI and cognitive decline but absolutely need access to high quality and timely MRI access ( cumulative brain Mets in the Non PCI cohort was higher)
πŸ“ sequencing therapies and new targets specially with Anti B7-H3 ADC ( and others like SEZ) weaved in with Tarlatamab will likely change the landscape of treatment and survival. Inclusion of rural patients with ECOG 2 in the global trials for these/similar agents is key as our population can be often older, frailer and with more commodities. #TAISHAN-302 #ARTEMIS-008